SEED Therapeutics
PrivateLast Round
Series A
Extension
Sep 23, 2025
Est. Valuation
$130M
Total Funding Raised
$80M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
SEED Therapeutics operates in Healthcare & Life Sciences and is based in King of Prussia, Pennsylvania. Its latest recorded funding round was a Series A Extension round in September 2025.
SEED Therapeutics is a biotechnology company that develops targeted protein degradation therapeutics using its proprietary RITE3™ molecular glue platform to treat diseases in oncology, neurodegeneration, and immunology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SEED Therapeutics Comparables
Compare SEED Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Degron Therapeutics | 88% | |
| Plexium | 88% | |
| Magnet Biomedicine | 88% |
For institutional investors. Book with your work email.
SEED Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Sep 23, 2025 | ||||
| Series A | Aug 6, 2024 | ||||
| Series A | Nov 13, 2020 |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 29, 116% of headcount.
- Sep 23, 2025
$30M round led by Eisai.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_awardAug 17, 2026
SEED Therapeutics, Inc. is also nominated for the 2025Prix Galien USA "Best Start-Up" Award.
For institutional investors. Book with your work email.
SEED Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SEED Therapeutics's valuation, stock price, and market status.
Is SEED Therapeutics a public or private company?
SEED Therapeutics is a private company.
What is the current stock price of SEED Therapeutics?
SEED Therapeutics is a private company, so its shares have no public market price. Caplight tracks SEED Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SEED Therapeutics worth (valuation)?
SEED Therapeutics's valuation is estimated at $130.0M based on funding round data.
Can I buy SEED Therapeutics stock?
SEED Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SEED Therapeutics's last funding round?
SEED Therapeutics's most recent funding round was Series A Extension on September 23, 2025.
Who are the main investors in SEED Therapeutics?
Investor information for SEED Therapeutics is not publicly disclosed.
Will SEED Therapeutics IPO soon?
No public IPO plans have been announced for SEED Therapeutics.
How can I track SEED Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in SEED Therapeutics's shares on secondary markets.